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CARVALHO(1), Gabriela M. ABIB ABI(1), Eliana M. RODRIGUES(3) & Silvia M.B. CAVALCANTI(1)
SUMMARY
This article reports the HPV status and cervical cytological abnormalities in patients attended at public and private gynecological
services from Rio de Janeiro State. It also comments the performance of each HPV DNA tests used. A set of 454 women from
private health clinics was tested by routine Capture Hybrid II HPV DNA assay. Among these, 58.4% presented HPV and nearly
90% of them were infected by high risk HPV types. However, this group presented few premalignant cervical lesions and no
invasive cervical cancer was registered. We also studied 220 women from low income class attended at public health system. They
were HPV tested by polymerase chain reaction using My09/11 primers followed by HPV typing with E6 specific primers. The
overall HPV prevalence was 77.3%. They also showed a high percentage of high squamous intraepithelial lesion-HSIL (26.3%),
and invasive cervical carcinoma (16.3%). HPV infection was found in 93.1% and 94.4% of them, respectively. The mean ages in
both groups were 31.5 and 38 years, respectively. In series 1, HPV prevalence declined with age, data consistent with viral
transient infection. In series 2, HPV prevalence did not decline, independent of age interval, supporting not only the idea of viral
persistence into this group, but also regional epidemiological variations in the same geographic area. Significant cytological
differences were seen between both groups. Normal and benign cases were the most prevalent cytological findings in series 1
while pre-malignant lesions were the most common diagnosis in the series 2. HPV prevalence in normal cases were statistically
higher than those from series 1 (p < 0.001), indicating a higher exposure to HPV infection. Women from both samples were
referred for previous abnormal cytology. However, socio-demographic evidence shows that women from series 1 have access to
treatment more easily and faster than women from series 2 before the development of pre-malignant lesions. These data provides
baseline support for the role of social inequalities linked to high risk HPV infection leading to cervical cancer. Broadly screening
programs and the development of safe and effective vaccines against HPV would diminish the toll of this disease that affect mainly
poor women.
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INTRODUCTION
Many human and animal papillomaviruses occur under latent status
and they can be detected on the health skin2. Human papillomavirus
(HPV) infection are largely transient, usually asymptomatic and most
of them without clinical consequence. In some countries 20-40% of
sexually active young women have detectable HPV genital infection
and the prevalence decreases with age3. The infection is associated to
different clinic illness at genital lower tract being considered the
commonest sexual transmitted viral infection1. Besides, the virus also
induces persistent infection in the genital tract carrying abnormal
epithelial changes which in few cases could progress from low grade
dysplasia to cervical cancer39. If a persistent infection with oncogenic
HPV precedes virtually all high-grade dysplasias or neoplasias, thus
the persistence for high-risk HPV DNA is a marker for current or
subsequent development of precursor lesions. So, sensitive screening
techniques should be useful to detect HPV virus giving support to
prevention of diseases.
HPV cervical disease screening is currently performed by cytology,
colposcopy and HPV DNA testing. For genome detection, the hybrid
capture is the most currently commercially available technique. It is
easy to perform in clinical settings and is suitable for automation18. In
the United States, HPV DNA Hybrid Capture II (HCII) testing was
recently approved for use with the Pap test for women 30 years old
and over12. However, this test does not recognize HPV types, but it is
able to distinguish between groups of high and low risk types to cancer.
Before the HCII introduction, in situ hybridization (ISH) was largely
used to detect HPV infection in cervical smears and biopsies. Although
useful8,16 ISH has been replaced by hybrid capture and the polymerase
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chain reaction (PCR) for the great majority of epidemiologic and
molecular studies. In fact, PCR has always proved to be a powerful
and sensitive tool for detecting oncogenic HPV and to conduct
epidemiological studies15,24,38,.
Concerning cervical cancer, Brazilian mortality rates per 100000
women were 4.58 in 20036.The average annual estimated rate for 2005
is 34.85 new cases per 10000 women in Rio de Janeiro, which is
considered a high average when compared to some Brazilian Sates7.
In Brazil, health care is universal. In attempt to control this disease,
routine cytology has been used in screening programs for cervical cancer
prevention. However, there is agreement about their relative low
sensitivity14. Governmental programs mitigate the lack of high sensitivity
by repeating tests every year or every three years for women having
consecutive normal Pap exams5. Cervical cancer has a natural history
with prolonged precancer stages that are easily detected and treated.
However, women who attended public healthcare, are far from early
detection and close surveillance following treatment for cervical cancer.
Despite the established causal association between infection and
high-risk HPV leading to cancer has been clearly established, HPV
testing is not part of current screening practice. The ideal screening
police would be cytology and HPV testing for women over 30 years,
as suggested by American Cancer Society43 but their cost-effectiveness,
the lack of infrastructure and trained personnel for health centers make
the start up of such preventive program very difficult.
In this present work two different female populations regarding
health care systems were analyzed in the light of cervical abnormalities.
Cytological diagnosis and HPV DNA testing by hybrid capture and
polymerase chain reaction were performed. The performance of each
HPV DNA assay was seen in the context of each set.
MATERIAL AND METHODS
Specimens - We studied 674 female patients attended at
gynecological services from public and private health care systems
from Rio de Janeiro State from 2000 to 2005. For better understanding,
we described each series according to the methodology utilized.
Series 1 - Health insurance coverage population - A cross-sectional
study population included 454 women enrolled from Laboratories
Sérgio Franco from January to December, 2000. Women were referred
to routine Papanicolaou exam at private clinics. If there was any
abnormality they were guided to HPV detection. The cervical smears
were collected by using a cervical cytobrush, and transported in Digene
Specimen Transport Medium (Digene Diag, Md). Cytological test was
developed and smears were classified based on Pap diagnosis group
which was converted to Bethesda nomenclature10. Cervical lesions were
classified as Normal, HPV infection (koilocytosis), ASCUS (atypical
squamous cells of undetermined significance), low grade squamous
intraepithelial lesions (LSIL-CIN I), high grade squamous
intraepithelial lesions (HSIL - CIN II, III/ in situ carcinoma), and
squamous invasive carcinoma (CA).
Hybrid capture II (HCII) - The assay kit detects low risk HPV
types 6,11,42,43,44 and high-risk types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68. Bound RNA-DNA hybrids were reacted with an
alkaline phosphatase-conjugated antibody directed against the hybrids.
A chemiluminescent compound, Lumi-Phos 530, was added as a
substrate for alkaline phosphatase. The light produced by ensuing
reaction was measured by a Luminometer and were expressed as relative
light units (RLUs). As a negative control, sonicated herring sperm DNA
in Digene transporting medium (100 µg/mL) was used. Triplicate
specimens of HPV 16 or HPV 11 DNAs at 1.0 pg/mL served as the
positive controls for high-risk and low-risk probes, respectively. Since
the amount of the light produced by the hybrid capture assay is
theoretically proportional to the amount of target HPV DNA, the results
could be viewed as quantitative.
Series 2 - Public health care people - A cross-sectional study
including 220 women was carried out from 2001 to 2005. They attended
at the Service of Cervical Pathology of Hospital Universitário Antonio
Pedro (HUAP), Universidade Federal Fluminense. Women participating
in the study came directly to outpatient clinic of the Hospital or derived
from public health services which provide cytological screening. These
services were situated in poor neighbor cities which do not hold an
adequate medical care. These women were enrolled for the study if
had abnormal cytology. Colpocytology was performed at the first or
subsequent visit to the Service. For women with high grade cervical
cytology, biopsies were performed. Cervical lesions were classified as
Normal, HPV infection (koilocytosis), ASCUS (atypical squamous cells
of undetermined significance), low grade squamous intraepithelial lesions
(LSIL-CIN I), high grade squamous intraepithelial lesions (HSIL - CIN
II, III, in situ carcinoma), and squamous invasive carcinoma (CA). The
Ethical Committee of Medicine College at the University approved the
protocol for collection as well the informed consent.
DNA extraction - Samples were incubated for four hours at 50 °C
in digestion buffer (10 mM Trishydrochloric acid pH 8.3, 1 mM EDTA
pH 8.0, .5% Tween 20, proteinase K; final concentration of 400 µg/
mL). Later, they were extracted with phenol-chloroform-isoamyl
alcohol (25:24:1). DNA was precipitated with one-tenth volume of 0.3
M sodium acetate and three volumes of 100% ice-cold ethanol, washed
with 70% ethanol, air-dried and suspended in 50 µL of sterile water.
PCR procedure - MY09/11 consensus primers, which amplify 450-
bp (base pair) DNA sequences within the L1 region of HPV, were used
to detect generic HPV DNA23. Amplification was carried out in 50 µL
of reaction mixture (1 X polymerase chain reaction [PCR] buffer, 200
mM dNTPs, 1.5 mM MgCl2, 50 pmol of each primer, 0.25 U unit of
Taq polymerase, and 5 µL of sample) with 35 cycles of amplification.
Each cycle included a denaturation step at 94 °C for one minute, an
annealing step at 55 °C for two minutes, and a chain elongation step at
72 °C for two minutes using DNA Thermal Cycler (Perkin Elmer,
CETUS). The beta-actin primers (0.1 pmol each), which amplify a
330-bp region of the human DNA, were used as an internal control.
Polymerase chain reaction products were analyzed on 1.3% agarose
gel with ethidium bromide staining for visualization of DNA under
ultraviolet light and their molecular weight was determined by
comparison with a 100-bp DNA ladder.
HPV typing was done by PCR using primers from the E6 gene
DNA sequences of HPVs 6, 11, 16, 18, 31, 33, 35 and 5831. These
primers yielded 230, 89, 134, 119, 97, 132, 186, and 100-bp fragments,
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respectively. The PCR included 35 steps at 94 °C for 30 seconds, 60 °C
for one minute, and 72 °C for one minute. Negative controls for
background contamination did not add to the DNA template. The PCR
run was completed by extension for 10 minutes at 72 °C. After DNA
extraction with phenol-chloroform-isoamyl alcohol, the PCR
amplification of generic human papillomavirus was done. To avoid
background contamination negative controls were performed without
DNA template. The primers Ac1 and Ac2, specific for the amplification
of a 330 base pairs (bp) fragment of the actin gene, were used as a
sample quality control17.
Statistical analysis - The statistical significance of results was
analyzed by using the X2 test for heterogeneity with Yates continuity
correction. Fisher exact test and a Mantel-Haentzel procedure for trend
were applied when appropriate. The significance level of tests (p) was
set at 0.05.
RESULTS
Series 1 – The average age of participants was 31.5 years, varying
from 15 to 70 years. Most of women presented either normal epithelium
(40.7%) or benign cervical lesions (52.5%). Few cases of premalignant
lesions were detected (7.27%) and no cancer cases were reported (Table
1). As shown in Table 2, HPV DNA prevalence is presented according to
the available cytological diagnosis: the overall prevalence of HPV DNA
in the studied group was 58.4% (265/454) ranging from 20.9% (41/196)
in normal cytology to 90.4% (104/115) in LSIL. From the 265 HPV
positive women, 25 (9.4%) had low risk HPV DNA to cancer; 156
(58.8%) had high risk HPV types and 84 (31.6%) had both groups. About
90% of the women were infected by at least one high risk HPV type.
Different mean age distribution patterns were detected in HPV
infected patients according to cytological diagnosis (Table 3). Normal
group was significantly different when compared to HSIL group (p <
0.0001). In the same way, most of women HPV infected had from 21-
30 years old (47.5%). In this sample, the HPV infection decreased as
the age increased (Table 4).
Series 2 - The eligible women aged from 14 to 82 years, mean age
38 years. They had low income status. In this series, we observed the
reverse of the pattern described above for series 1 on several aspects.
Normal epithelium was found in only 20% (p < 0.001 when compared
to series 1) of these women while premalignant and malignant lesions
reached 42.72% (p < 0.001) of the total sample. Out of 36 women
(16.36%) carried cervical cancer. ASCUS and LSIL prevalence were
similar in both groups (Table 1).
HPV infection status was 77.3% (170/220) in this series. The overall
prevalence was statistically higher than series 1 (p < 0.001). With respect
to HPV prevalence by mean age according the level of abnormality
detected by cytology, we had to point the low mean age of the women
carrying HSIL (36.2) and invasive cancer (50.9) (Table II). In a hallmark
contrast with the series 1, a high HPV infection incidence was detected
among all age groups (Table 4).
The HPV frequency ranges from 43.2% (19/44) in normal cervical
epithelium to 94.4% (34/36) among cancer. HPV types detected in the
series 2 were grouped in low and high risk types for standardizing the
results (Table 2). Multiple infections (two or more HPV types) were
detected in 15.8% (27/170) of HPV positive smears. Those caused by
two low risk HPV types were only associated to benign abnormalities
Table 1
Prevalence of cytological diagnosis among series 1 and series 2 women
Cytology Series 1 Series 2 p
Number (%) Number (%)
Normal 185 (40.74) 44 (20.0) < 0.001
HPV 110 (24.23) 30 (13.64)  0.001
ASCUS 11 (2.42) 6 (2.72) 0.81
LSIL 115 (25.33) 46 (20.91) 0.2
HSIL 33 (7.27) 58 (26.36) < 0.001
CA 0 36 (16.36) < 0.01
TOTAL 454 (100) 220 (100)
Table 2
Prevalences of HPV groups according to the cytological diagnosis by HCII among women of private health care and by PCR among women of public health care
Cytology Normal HPV ASCUS LSIL HSIL CA TOTAL
Series 1
GRUPO Aa 7 8 0 10 0 0 25
GRUPO Bb 16 55 2 66 17 0 156
GRUPO A+Bc 15 29 1 28 11 0 84
Prevalence 38 (20.5%) 92 (83.6%) 3 (2.7%) 104 (90.4%) 28 (84.8%) 0 265 (58.4%)
Series 2
Lowd risk 5 5 1 8 1 1 21
Highe risk 11 11 3 20 41 22 109
Mixedf 0 1 0 4 7 9 21
U 3 6 0 3 5 2 19
Prevalence 19 (43.2%) 23 (76.7%) 4 (66.7%) 35 (78.3%) 54 (93.1%) 34 (94.4%) 170 (77.3%)
aLow risk HPV 6,11,42,43,44; bHigh risk HPV 16,18,31,33,35,39,45,51,52, 56,58,59,68; cMixed infection (low+high risk HPV); dLow risk HPV 6,11; eHigh risk HPV
16,18,31,33,35,58; fLow and high risk types in mixed infection; U: undetermined types.
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(3.5% (6/170). Mixed infections (low and high risk HPV) were found
in 12.5% (19/170) of the positive smears. Most of the HPV could be
typed with the specific primers. However 11.1% (21/170) were not
identified by using specific primers and they were referred as
undetermined types.
DISCUSSION
This work does have limitations. We based our outcome in different
HPV DNA technologies to compare different samples. The two methods
have in general a good agreement, ranging from 76.5%29 to 99.5%4.
Since the goal of our work was to investigate two female populations
attended at different health services, accessing different methodologies,
this protocol might not affect our objective.
Both HPV tests had good agreement (p < 0.0001) with cytology
and showed to be a useful tool when combined to cytology. Women
from series 1 were tested for HPV infection by HCII. It is appropriated
for screening infection because it detects a broad-spectrum of HPV
types. This procedure makes it very expensive for low income people.
By other side, HCII is not useful for genotyping and it cannot distinguish
between persistent infection and re-infection20. So, mixed infection
could not be detected in the series 1. Besides, HPVs not yet typed
cannot be identified by HCII therefore reducing the sensitivity of the
test, differently from PCR using generic primers that can screen HPV
by amplified conserved region.
The goal of our work was highlight disparities in cervical cancer
incidence. Prevention throughout Papanicolaou exams is the hallmark
in reducing cervical cancer. Although women from both samples were
referred for previous abnormal cytology, people from series 1 have
access to a treatment more easily and faster than women from series 2
before the development of pre-malignant lesions. Besides, many doctors
guide their patients with minor cytological changes to HPV DNA
testing. Women from series 2 have many barriers to complete the follow-
up on time. Delays in care for abnormal cervical cytology can contribute
to a later stage in diagnosis.
Significant cytological differences were seen between both groups.
Normal and benign cases were incident in series 1 while pre-malignant
lesions were found mainly in the series 2 (Table 1). Instead, HPV
prevalence in normal cases were statistically higher than those from
series 1 (p < 0.001), indicating a higher exposure to HPV infection.
Differences in HPV infection were found in ASCUS cases. The
restricted number of cases in both series did not allow us evaluate this
finding. Under the term ASCUS (atypical squamous cells of uncertain
significance), cytologists referred all the inconclusive diagnostics. Not
for sense, it is the most well-defined guideline for HPV DNA testing
after equivocal Pap test results.
Private gynecologic clinics are not reference’s guide to cervical
pathology diagnosis. Therefore, the lack of this disease could be an
expected result. However, gynecologic clinics might track high grade
cervical lesions, which are precursor lesions normally asymptomatic.
We have found 7.27% of these lesions from series 1 versus 26.36%
from series 2. Besides, the laboratory Sergio Franco services a great
network of clinics, then we could expect few cancer cases among women
from series 1, if they existed.
Women from this set have received a regular health care in private
clinics and had higher education and economic level to get an annual
screening test. If any abnormal cervical were recorded, complementary
HPV DNA testing (HCII) were done at private laboratory diagnosis.
In spite of cancer absence and reduced premalignant cases, 92% of the
HPV positive patients carried high risk HPV types. Although HPV
infection was higher in the series 2 (p < 0.001), the rates of high risk
HPV types were similar in both groups (Table 2).
The result is remarkable when compared to other series not
randomly selected11,37. However, several works mention false-positive
results seen in HCII test induced by crossing-reacting among high-
risk probe cocktail with HPV types that are not represented in the
probe mix33,34,41. So, such high prevalence of oncogenic types may be
overestimated. In spite some caveats, a panel of representative American
experts recommended combined HCII and Pap screening to guide
American clinicians. But these experts recognize that they may change
as new data continues to evolve42.
The mean ages in groups 1 and 2 were 31.5 and 38 years, respectively.
Table 4 shows that HPV infected women from private clinics tended to
Table 4
HPV positivity according to the age of patients
Age intervals 11-20 21-30 31-40 41-50 51-60 61-70 > 70
Series 1 (n = 265) 50 126 56 24 7 2
                      (%) 18.8 47.5 21.1 9.0 2.6 0.7
Series 2 (n = 170) 8 46 54 35 16 6 5
                      (%) 4.7 27.0 31.7 20.5 9.4 3.5 2.9
Table 3
Mean age of HPV infected women from series 1 and 2 classified according to the cytological diagnosis
Cytological diagnosis mean age Normal ASCUS HPV LSIL HSIL CA
Series 1 27.0 32.5 27.9 34.8 49.3 -
Series 2 37.4  29.7 45.5 35.3 36.2 50.9
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be younger than those attending at healthcare public services. According
to several authors, transient infections are prevalent in young women13,25,26.
So, virus clearance in people from series 1 could be as likely as HPV
infection in the series 2 trended towards viral persistence.
Clearance is a common event compared to uncommon persistence.
Genital infections tend to resolve spontaneously as do warts or low
grade cervical lesions. A non-resolved problem related to natural history
of HPV infection is the possibility of incomplete viral clearance that
can result in viral latency40. Authors describe that for HPV, persistence
is characterized by finding the same DNA type detected two or more
times in over a period while latency implies that no HPV DNA is
detectable by conventional molecular tests but that very small foci of
cells maintain infection at low DNA copy numbers. Data about cervical
cancer arising after a period of viral latency is largely unkown40. Recent
studies suggest that viral load represent an important prognostic tool
related to cancer establishment22,43. Our data showed that in series 1,
HPV prevalence declined with age (66.3% in women under 30 years)
what is consistent with viral transient infection. In series 2, HPV
prevalence did never decrease (68% in women up to 30) supporting
not only the idea of viral persistence but also regional (socio-
demographic) epidemiological variations in the same geographic area.
This is an important data for further studies about clearance, persistence
and latency. Studies with highly exposed prostitutes have shown
decrease in HPV prevalence with ages, indicating loss of detectable
HPV or type-specific immunity if reinfection occurs19.
Women from the series 2 were tested for DNA HPV by PCR, a high
sensitive technique considered as the gold standard for HPV infection.
However, there are several conditions, such as the DNA extraction
procedures, differences for the detection of HPV infection in sampling
methods and sample transport/storage, and especially the use of different
polymerases for the PCR reactions that can affect test performance, as
reported by MUÑOZ et al.28. For HPV DNA detection, we used the
protocol employing the consensus primers My09/11, directed to a highly
conserved region of the L1 gene, capable of detecting all mucosal types23.
Improvements developed for this technique increase widely the HPV
detection in cervical cancer cases reaching nearly 96.6% of those cases27.
In our study, by using this protocol, we detected HPV infection in 94.4%
of the cancer cases. This average did not differ significantly from those
found in worldwide publications3,27,28.
Multiple infections have been associated to promiscuous behavior36.
For standard analysis between the two series, we considered co-
infection at least one low and one high risk types in the same patient.
This occurrence was observed in 31.6% (series 1) and 12.3% (series
2) of the women studied. Probably, in the HUAP patients, the small
quantity of type specific primers restricted this finding. Our results
are also underestimated in the series 1 due to incompatibility of HCII
test to show more than one high risk type in the same smear. It is
noteworthy that 26.4% of CA cases were co-infected, with a significant
linear trend when we compared to remained cervical lesions.
Undetermined HPV types are a relative common finding in several
works9,15,30,35. These authors could not type about 6-20% of the HPV
positive samples by restriction fragment length polymorphism (RFLP)
detecting a broad range of HPV types. In series 2, we failed typifying
11.1% of the samples. Interestingly, the lowest rate of untyped HPV
was found in cancer cases (6%), showing that the high risk types 16
and 18 are responsible for most of them (72.2%).
In this study, we focused on two female populations largely infected
by high risk HPV types. However, cervical cancer was seen only in
women from low income class. Besides persistent infection, cancer
development results from socioeconomic inequalities. Income,
education, domicile far from primary health care setting, transportation
difficulty, and lack of health insurance coverage affect the access to
appropriate early detection and treatment of cervical cancer and their
precursor lesions. Hence, some of these factors account for the
difference in mean age seen among two series. So, we highlighted the
role of social inequalities in cervical linked to the HPV status. It is
important to note that also in developed countries with decreased
cervical cancer mortality, as in the United States, cytological screening
has not been equally accessible to all subpopulations and incidence
and mortality from cervical cancer are higher in ethnic minorities and
poor women21. In fact, in this country, there is a decrease of more than
half of the incident cases of invasive cervical cancer diagnosed in
women who have not been adequately screened. PARIKH et al., 200332,
surveying 57 case control studies, also emphasize the importance of
the adequate cervical screening programmes in the high cervical cancer
incidence observed in developing countries. In our country, although a
national prevention policy exists, it performs inadequately. Therefore,
a organized screening regional programme would be the only effective
means in reducing the unequal burden of cervical cancer. The
development of safe and effective vaccines against HPV also would
diminish the toll of this disease that disproportionately affects poor
women.
RESUMO
Papilomavírus humano e anormalidades cervicais em mulheres
do sistema de saúde privado e público no Estado do Rio de
Janeiro, Brasil
Este artigo analisa a infecção por HPV e anormalidades citológicas
cervicais encontradas em pacientes atendidas em serviços ginecológicos
dos sistemas de saúde público e privado do estado do Rio de Janeiro.
O trabalho também avalia os testes utilizados para detecção de DNA
do HPV em cada população estudada. Um grupo de 454 mulheres
oriundas de serviços da rede privada de saúde foi testado por Captura
do Híbrido II. Destas, 58,4% apresentaram infecção por HPV e cerca
de 90% delas estavam infectadas por HPV de alto risco. Este grupo,
entretanto, apresentava poucos casos de lesões cervicais pré-malígnas
e nenhum caso de câncer. Estudamos, também, 220 mulheres de baixo
nível econômico atendidas no serviço de saúde pública que foram
testadas para HPV pela reação da polimerase em cadeia utilizando-se
os oligonucleotídeos My09/My11. A identificação dos tipos foi efetuada
por amplificação com oligonucleotídeos específicos para a região E6
do genoma viral. A prevalência de HPV nesta população foi de 77.3%,
observando-se uma alta porcentagem de casos de neoplasias
intraepiteliais cervicais de alto grau (26,3%) e de carcinoma cervical
invasivo (16,3%). A infecção por HPV foi achada em, respectivamente,
93,1% e 94,4% destes casos. A média de idade em ambos os grupos
era de 31,5 e 38 anos, respectivamente. Na série 1, a prevalência da
infecção por HPV decresce com a idade, enquanto na série 2 ela não
desaparece, dando suporte não só à idéia de persistência viral neste
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grupo, mas também a variações epidemiológicas na mesma área
geográfica. Diferenças significativas foram vistas nos dois grupos.
Casos normais e benignos foram incidentes na série 1, enquanto as
lesões malígnas predominaram na série 2. Ao contrário, casos normais
infectados por HPV eram prevalentes na série 2 (p < 0.001), indicando
maior exposição ao vírus. Embora as mulheres de ambos os grupos
tenham sido incluídas no estudo por apresentarem citologia anormal,
evidências sócio-demográficas demonstram que mulheres da série 1
tem acesso mais fácil e rápido ao tratamento do que as mulheres da
série 2 antes que as lesões pré-malígnas se desenvolvam. Estes
resultados fornecem dados sobre o papel das desigualdades sociais
associadas à infecção por HPV de alto risco na progressão do câncer
cervical. Programas de prevenção abrangentes e o desenvolvimento de
vacinas eficazes e seguras contra o HPV poderiam reduzir o tributo
desta doença que afeta principalmente mulheres pobres.
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